Evidence map›Paper›PMID 29725416›Full record

ArticleOncology letters2018

Baseline prostate-specific antigen levels following treatment with abiraterone acetate as a prognostic factor in castration-resistant prostate cancer.

Tasuku Hiroshige, Yoshiro Eguchi, Osamu Yoshizumi, Katsuaki Chikui, Hisaji Kumagai, Yoshihiro Kawaguchi, Rei Onishi, Tokumasa Hayashi, Kouta Watanabe, Tomotaro Mitani and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncology letters, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Tasuku HiroshigeDepartment of Urology, St. Maria Hospital, Kurume, Fukuoka 830-8543, Japan.
Yoshiro EguchiDepartment of Urology, St. Maria Hospital, Kurume, Fukuoka 830-8543, Japan.
Osamu YoshizumiDepartment of Urology, St. Maria Hospital, Kurume, Fukuoka 830-8543, Japan.
Katsuaki ChikuiDepartment of Urology, Kurume University School of Medicine, Kurume, Fukuoka 830-0011, Japan.
Hisaji KumagaiDepartment of Urology, Yame General Hospital, Yame, Fukuoka 834-0034, Japan.
Yoshihiro KawaguchiDepartment of Urology, Chikugo City Hospital, Chikugo, Fukuoka 833-0041, Japan.
Rei OnishiDepartment of Urology, Kurume General Hospital, Kurume, Fukuoka 830-0013, Japan.
Tokumasa HayashiDepartment of Urology, Kurume University Medical Center, Kurume, Fukuoka 839-0863, Japan.
Kouta WatanabeDepartment of Urology, Takagi Hospital, Okawa, Fukuoka 831-0016, Japan.
Tomotaro MitaniDepartment of Urology, Omuta City Hospital, Omuta, Fukuoka 836-8567, Japan.
Koujiro SaitoDepartment of Urology, Saiseikai Omuta Hospital, Omuta, Fukuoka 837-0916, Japan.
Tsukasa IgawaDepartment of Urology, Kurume University School of Medicine, Kurume, Fukuoka 830-0011, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The aim of the present study was to investigate the prognostic factors associated with progression-free survival (PFS) and overall survival (OS) times in patients with castration-resistant prostate cancer (CRPC) who received treatment with abiraterone acetate (AA) in routine clinical settings. A total of 93 patients treated with AA between September 2014 and February 2017 were selected and their medical records were analyzed retrospectively. The median PFS time of docetaxel (DTX)-naïve patients was 171 days, and that of post-DTX patients was 56 days. The OS time of DTX-naïve patients did not reach the median. The median OS time of post-DTX patients was 761 days. Multivariate analyses identified baseline prostate-specific antigen (PSA) level prior to treatment with AA and the PSA response rate as independent prognostic factors for PFS time, and baseline PSA prior to treatment with AA as the only independent prognostic factor for OS time. The results of the present study indicate that the baseline PSA level prior to treatment with AA is a notable prognostic factor in patients with CRPC.

Indexed as

abiraterone acetatebaseline prostate-specific antigencastration-resistant prostate cancer

Identifiers

PMID29725416
PMCPMC5920147

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.